Kliqqo

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Kliqqo, are a calcium‑channel blocker and a selective β1‑adrenergic antagonist respectively, presented as oral tablets for systemic use. They are employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Kliqqo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Our distribution network ensures timely delivery and reliable product traceability across multiple continents.

Kliqqo combines amlodipine and nebivolol to treat hypertension, a condition characterized by elevated arterial pressure.

Essential hypertension: provides consistent reduction of systolic and diastolic blood pressure. Isolated systolic hypertension: helps lower high systolic readings while maintaining diastolic stability. Secondary hypertension (renovascular, endocrine): contributes to blood pressure control when used as part of a comprehensive regimen. Hypertensive patients with cardiovascular risk: improves vascular compliance and reduces cardiac workload.

Like all antihypertensive agents, Kliqqo may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache may occur during treatment. - Peripheral edema: swelling of ankles or feet is frequently reported. - Dizziness: light‑headedness, especially after the first doses. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Bradycardia: abnormally slow heart rate that may require medical attention. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Angioedema: swelling of face, lips, tongue, or throat.

Before initiating Kliqqo, clinicians should consider several safety measures.

Blood pressure monitoring: check BP regularly after initiation and dose changes. Cardiac assessment: evaluate heart rate and conduction in patients with known arrhythmias. Liver function: assess hepatic status before starting therapy and periodically thereafter. Concomitant antihypertensives: adjust doses to avoid excessive hypotension. Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Kliqqo may interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase amlodipine levels. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can raise nebivolol concentrations. - Other potent antihypertensives (e.g., clonidine, hydralazine): risk of additive hypotension. - Grapefruit juice: enhances amlodipine exposure leading to possible toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate blood‑pressure lowering effect. - NSAIDs: can blunt antihypertensive response. - Additional calcium‑channel blockers: increased risk of edema. - Antacids containing aluminum or magnesium: may affect absorption of amlodipine.